Shubh Gupta is the visionary Chief Scientific Officer at Immumem Therapeutics, where he leads the development of breakthrough, iPSC-derived memory cell therapies designed to revolutionize cancer treatment. With a robust background in stem cell research, immuno-oncology, and regenerative medicine, Shubh has dedicated his career to overcoming the limitations of traditional cell therapies by enhancing immunological memory and ensuring durable tumor control. Under his leadership, the novel MemGen platform is being engineered to address critical challenges such as immune cell exhaustion and relapse prevention in solid tumors.
An alumnus of a prestigious institution, Shubh’s pioneering research has consistently pushed the boundaries of cellular therapeutics. His work has not only been instrumental in advancing scientific understanding in the field but also in translating cutting-edge laboratory innovations into scalable, off-the-shelf solutions. Leveraging the state-of-the-art facilities and expertise, Shubh has accelerated Immumem’s in vitro studies and paved the way for rapid in vivo validation, streamlining the path toward clinical success.
Passionate about improving patient outcomes and reducing the exorbitant costs of existing therapies, Shubh Gupta continues to drive Immumem Therapeutics toward transforming the future of cancer treatment on a global scale.
